The Hepatocellular Carcinoma market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Hepatocellular Carcinoma: An Overview
Hepatocellular Carcinoma (HCC) is the most common type of primary liver cancer. It is a malignant tumour of hepatocytes, which may exhibit any or all of the cytologic and/or architectural characteristics of hepatocellular differentiation, along with features of malignancy.
The treatment is generally recommended at early-stage HCC and may not be recommended to treat patients with later stages of the disease. These treatments are surgery, radiofrequency ablation, percutaneous ethanol injection, radiation therapy and tyrosine-kinase inhibitors, and recently approved (PD 1)-blocking antibody and monoclonal antibodies. Flaws in the designing clinical trial, liver toxicity, lack of significant antitumor potency of tested drugs, etc. have led to failures of clinical trials.
Hepatocellular Carcinoma Market Key Facts
-
According to the study published by Singal et al., the worldwide incidence of HCC is heterogeneous because of the variable prevalence of underlying risk factors. It is estimated that 72% of cases occur in Asia (more than 50% in China), 10% in Europe, 7.8% in Africa, 5.1% in North America, 4.6% in Latin America and 0.5% in Oceania.
-
According to DelveInsight’s analysis, it has been observed that HCV based HCC cases are more prominent in comparison to HBV, alcoholic liver disease and metabolic syndrome based HCC cases.
-
Among the European five countries, Italy had the highest incident population of Hepatocellular Carcinoma, followed by France and Germany. On the other hand, Spain had the lowest incident population of Hepatocellular Carcinoma.
Hepatocellular Carcinoma Market
The Hepatocellular Carcinoma Market Size is anticipated to increase during the study period owing to the increasing prevalent population of Hepatocellular Carcinoma patients and the expected entry of premium price assets such as gene therapy, combination therapies.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Hepatocellular Carcinoma market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the Hepatocellular Carcinoma market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Hepatocellular Carcinoma Epidemiology
The epidemiology section covers insights about the historical and current Hepatocellular Carcinoma patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Hepatocellular Carcinoma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hepatocellular Carcinoma market or expected to get launched in the market during the study period. The analysis covers Hepatocellular Carcinoma market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Hepatocellular Carcinoma Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Get the PDF Sample of the Report:- https://www.delveinsight.com/sample-request/hepatocellular-carcinoma-market
Hepatocellular Carcinoma Therapeutics Analysis
The available therapeutics treatment options in Hepatocellular Carcinoma Landscape aim to reduce complications arising from blood accumulating in joint spaces and/or other tissues and organs. The dynamics of the Hepatocellular Carcinoma market is anticipated to change in the coming years owing to the improvement the healthcare spending across the world and the discovery of new targets.
Some of the key companies in the Hepatocellular Carcinoma Market include: BeiGene Eisai Astra Zeneca Tiziana Life Sciences CStone Pharmaceuticals And many others. Hepatocellular Carcinoma Therapies covered in the report include: CS1003 Milciclib Tislelizumab (BGB-A317) Durvalumab (Imfinzi) Durvalumab and Bevacizumab Pembrolizumab and Lenvima And many more. Get More Detailed Insights into the Emerging Therapies & Key Companies:- https://www.delveinsight.com/sample-request/hepatocellular-carcinoma-market Table of Content 1. Key Insights 2. Executive Summary 3. Hepatocellular Carcinoma Competitive Intelligence Analysis 4. Hepatocellular Carcinoma Market Overview at a Glance 5. Hepatocellular Carcinoma Disease Background and Overview 6. Hepatocellular Carcinoma Patient Journey 7. Hepatocellular Carcinoma Epidemiology and Patient Population 8. Hepatocellular Carcinoma Treatment Algorithm, Current Treatment, and Medical Practices 9. Hepatocellular Carcinoma Unmet Needs 10. Key Endpoints of Hepatocellular Carcinoma Treatment 11. Hepatocellular Carcinoma Marketed Products 12. Hepatocellular Carcinoma Emerging Therapies 13. Hepatocellular Carcinoma Seven Major Market Analysis 14. Attribute Analysis 15. Hepatocellular Carcinoma Market Outlook (7 major markets) 16. Hepatocellular Carcinoma Access and Reimbursement Overview 17. KOL Views on the Hepatocellular Carcinoma Market. 18. Hepatocellular Carcinoma Market Drivers 19. Hepatocellular Carcinoma Market Barriers 20. Appendix 21. DelveInsight Capabilities 22. Disclaimer *The table of contents is not exhaustive; the final content may vary. Request Sample Report here:- https://www.delveinsight.com/sample-request/hepatocellular-carcinoma-market Other Latest Reports By DelveInsight DelveInsight’s “Renal Vasculitis Market” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, Renal Vasculitis market size, share, trends in the 7MM as well as the emerging therapies and key companies actively working in the domain. About DelveInsight DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance. Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/